title: Aliskiren-induced QT interval prolongation.
abstract: Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is the first approved pharmaceutical to manage hypertension by direct renin inhibition. With the introduction of novel drugs and mechanisms of action comes the challenge of monitoring for new unreported adverse events. The side effect profile for aliskiren has not yet been fully described. We describe the first apparent report of aliskiren-induced QT prolongation resulting in torsades de pointes.
authors.affiliation: Pharmacy Department, Sanford USD Medical Center, Sioux Falls, SD 57117-5039, USA. peitzg@sanfordhealth.org
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Peitz
authors.forename: Mark A
authors.initials: MA
authors.lastname: Malesker
authors.forename: S George
authors.initials: SG
authors.lastname: Sojka
mesh_terms: D000368:Aged; D000577:Amides / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D005260:Female; D005650:Fumarates / Q000009:adverse effects*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D013015:Sotalol / Q000009:adverse effects
chemical_list: D000577:Amides; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D005650:Fumarates; C446481:aliskiren; D013015:Sotalol